

INDEX

- Activins, mesoderm inducing factors, 123–124
- Alzheimer's disease, chromaffin cell grafting, 108
- Amphibians, limb regeneration, 191–196
- Antiestrogens, chemoprevention and therapy of epithelial malignancy, 145–147
- Apical ridge, effects on mesenchyme, 201
- Astrocytes, effect of bFGF, 103
- Betaglycan, soluble/insoluble form, 136
- Binding proteoglycans, 131–137
- Blastema,
 - newt limb blastema, 194
 - retinoic acid receptors, 196
- Blastula, mesoderm induction, 119–129
- Bombesin,
 - action on Swiss 3T3 cells, 45–46
 - mitogenic stimulation, 1–3
- Bombesin receptor,
 - coupling to G protein, 48–52
 - modulation by guanine nucleotides, 47–48
 - stabilization by Mg^{2+} , 47
- Bone morphogenetic proteins,
 - 1–7, schematic representation, 151
 - identification and molecular cloning of growth factors, 150–151
 - in vivo* activity of BMP-2, 154–155
 - influencing bone development, 149–155
 - interrelationships and homologies with other TGF- β superfamily members, 151–153
 - mRNAs, 153–154
- Bradykinin, mitogenic stimulation, 1–3
- Brain tumors, basic fibroblast growth factor, 108
- Brain-derived neurotrophic factor (BDNF),
 - sequence homology to nerve growth factor, 97
- Ca^{2+}
 - Ca^{2+} -dependent Ca^{2+} release, 1–3
 - internal stores, 1–3
 - oscillation mechanisms, 1–3
- Cadherins, and *lgl* encoded surface molecule homology, 179
- Carcinogenesis, and transforming growth factors, 139–147
- Cartilage, differentiation, 202–203
- Cell activation, cytosolic ions and messengers, imaging and manipulation, 1–3
- Cell development, developmental signals, 199–206
- Cell-cell interactions, limb development, 201
- Central nervous system lesions, 106–107
- Cerebrospinal fluid, basic fibroblast growth factor, 108
- Chick limb, retinoids, 195–196
- Chimeras, mapping and dissociating properties of PDGF A and B, 31–40
- Chromaffin cells, basic fibroblast growth factor, 104–105
- COS-1 cells, *int-2* transcription, 91–94
- Cytokines *see* Interleukins; Tumour necrosis factor
- Cytosolic free Ca^{2+} , 1–3
- Cytosolic ions and messengers, imaging and manipulation during cell activation, 1–3
- Developmental signals, limb development, 199–206
- DIA/LIF *see* Differentiation inhibiting activity/leukemia inhibitory factor
- Diacylglycerol, cytosolic messenger, 1–3
- Differentiation inhibiting activity/leukemia inhibitory factor, 75–83
 - alternative forms, 80
 - G protein, 78
 - PIN-type, 78
 - receptor, 77–82
 - tyrosine kinase receptor, 78
- Differentiation inhibiting activity/leukemia inhibitory factor receptor,
 - control of stem cell function, 77–78
 - molecular and biological characteristics, 78–80
 - multiple functional forms, 80–81
 - stem cell derived signals, 82
- Drosophila*,
 - genes,
 - boss* gene, 159
 - ectopic expression of *sevenless* and *rough*, 157–167
 - lethal *fat* mutations, pharate adults, 176
 - and mutant phenotypes, 184
 - showing homology to growth factor receptors, 184
 - ultrabithorax* gene, expression, 162
 - genetic control of cell proliferation in imaginal discs, 169–185
 - imaginal disc neoplastic overgrowth mutations, 173–180
 - developmental delay, 181–182
 - maternal effects, 182–183
 - tissue autonomy, 180–181
 - imaginal disc neoplastic overgrowth phenotype, *dlg* and *lgl*, 177
 - positional signalling in the developing eye, 157–167
 - wing development,
 - growth patterns and cell regeneration, 172
 - spatial patterns, 171
- EGF *see* Epidermal growth factor
- Embryonal carcinoma cells, lines, 90
- Embryonic stem cells, growth and differentiation factors, 75–83
- Eosinophilic progenitor cells, promotion by, interleukin 5, 67
- Epidermal growth factor,
 - structure-function relationships, 5–9

- variants, mitogenic activity, 5–9
- Epidermal growth factor receptor, *Drosophila*, homology to various genes, 184
- Epidermal growth factor-like growth factor, *Drosophila*, homology to various genes, 184
- Epithelial malignancy, chemoprevention and therapy, 145–147
- Eye development,
 - insect compound eye, ectopic expression of *sevenless* and *rough*, 157–167
 - positional signalling in *Drosophila*, 157–167
- F9 embryonal carcinoma cells, 90
- FDCP-mix cells, myeloid growth factor-stimulated development, 69–70
- Feather patterns, quail, 204–205
- b-Fibroblast growth factor,
 - action on neuroectodermal cells *in vivo*, 105–107
 - basic and acidic, 87–88, 97–98
 - cells and tissues expressing bFGF, 99
 - chromaffin cells, 104–105
 - functions outside the nervous system, 99–100
 - mesoderm induction, 119–129
 - molecular properties, 98–99, 100–101
 - muscle differentiation, 204
 - in neurons and glial cells, 101–104
 - pattern formation, 206
 - possible clinical applications, 107–108
 - receptors, 105–106
 - structure, 99
- Fibroblast growth factor,
 - human homologues, amino acid sequences, 88
 - int-2* gene, 87–95
 - K-FGF, 82, 95
- Fibroblast growth factor receptor, in *Xenopus*, 127
- K-Fibroblast growth factors, 82
- G proteins,
 - DIA/LIF, 78
 - pertussis toxin-sensitive, 45–46
 - role in bombesin signal transduction pathways, 45
- Gap junctions, polarizing region communications, 206
- Gastrin releasing peptide, mitogenic activity, Swiss 3T3 cells, 44
- Gestodene, binding site in malignant mammary tissue, 145–146
- Glial cells, effect of bFGF, 103
- Granulocyte colony-stimulating factor, 66
- Granulocyte-macrophage colony-stimulating factor, 65–66
- Growth factor receptors, *Drosophila*, showing homology to genes, 184
- Growth factors,
 - Drosophila*, showing homology to genes, 184
 - influencing bone development, 149–155
 - mesoderm patterns, 205–206
- Growth inhibition, and transforming growth factors, 139–147
- Guanine nucleotide regulatory proteins *see* G proteins
- Guanosine-5'-O-(3-thiotriphosphate) (GTP γ S), 1–3
- Haemopoiesis,
 - basic mechanisms, 60
 - cell growth factors, biochemistry and biology, 57–70
 - CFU-S assay, 59
 - HPP-CFC assay, 59
 - model systems, 67–68
- Heat shock protein 70, *Drosophila*, *rough* minigene, 161
- Heparin, binding to fibroblast growth factors, 123
- HL-60 cell line, 68–70
- Homeobox genes,
 - potential targets for retinoic acid regulation, 195
 - rough*, lethal indiscriminate expression, 161
- IGFI *see* Insulin-like growth factor
- Imaginal discs,
 - genetic control of cell proliferation in *Drosophila*, 169–185
 - model of cell proliferation, 170
 - neoplastic overgrowth mutations, 173–180
 - X-irradiation, 171
- Indicator dyes, fluorescence, 1–3
- Inositol 1,4,5-trisphosphate,
 - cytosolic messenger, 1–3
 - mitogenic activity of PMT, 52
- Insect compound eye, positional signalling in *Drosophila*, 157–167
- Insulin receptor, 5–9
- Insulin-like growth factor, structure, simulations of molecular dynamics, 5–9
- Insulin-like growth factor receptor, types 1 and 2, 5–9
- Int-2* gene,
 - embryonic expression, 89–90
 - fibroblast growth factor family, 87–95
 - structure, 90
 - timing of transcription, 90
- Int-2* protein,
 - alternative initiation codons, 93–95
 - functions, 95
 - synthesis and processing, 90–93
- Interleukin 1,
 - and 5-fluorouracil, 62
 - activity, 62
- Interleukin 3, activity on myeloid progenitor cells, 61–62
- Interleukin 4, differentiation of multipotent cells, 62–63
- Interleukin 5, promotion of eosinophilic progenitor cells, 67
- Interleukin 6,
 - and action of DIA/LIF, 78
 - effects on multipotent cells, 63–64
- Interleukins, human interleukin for DA cells (HILDA), bioregulatory activities, 79
- Kallikreins, serine proteases, 19–29
- Keratinocyte growth factor, amino acid sequence, 88–89

- Leukemia inhibitory factor, 75–83
- Lgl* encoded surface molecule, homology to cadherins, 169–185
- Limb development,
pigment patterns, 204–205
progress zone, 200
signals, 199–206
- Limb regeneration, and retinoic acid, 191–196
- Lymphotoxin, structure, compared with tumour necrosis factor, 14–16
- M1 cell line, 69–70
- Macrophage colony-stimulating factor, 67
- Macrophage inflammatory protein 1 *see* Stem cell inhibitor
- Mammary tumours,
binding site for gestodene, 145–146
int-2 gene as proto-oncogene, 89
- Mesoderm inducing factors,
bFGF, 128–129
biological activity, 124–125
candidates, 122–124
FGF family, 97–108
Xenopus, 119–129
- Mesoderm patterns, growth factors, 205–206
- Messengers, cytosolic, 1–3
- Mink lung epithelial cells *see* Mv1Lu epithelial cells
- Mitogenic signalling, G protein and bombesin receptor, 43–53
- Mitogenic stimulation, 1–3
- Mitogens, *Pasteurella multocida* toxin, 52
- Morphogens, retinoic acid, 191–196
- Mouse mammary tumour virus (MMTV), *int-2* gene, 89
- Muscle,
activin A induced, 124
differentiation, 204
- Mv1Lu epithelial cells, lack of response to TGFs, 134–136
- Myc*, *Drosophila*, homology to various genes, 184
- Myeloid growth factor-stimulated development, cell lines, 68–70
- Myeloid haemopoietic cell growth factors, biochemistry and biology, 57–70
list, 58
- Na⁺,
influx, 1–3
intracellular [Na⁺], 1–3
- Nerve growth factor,
murine,
7S NGF precursor, 19–29
crystal forms, 26
electron micrograph, 27
UV spectra, 28
X-ray crystallography, 19–29
sequence homology to brain-derived neurotrophic factor, 97–98
various species, sequence alignment, 20
- β -Nerve growth factor,
amino acid sequence, 23
multiple isomorphous replacement, 21–24
protein–protein interaction with α and γ -NGF, 28
purification and crystallisation, 21
- γ -Nerve growth factor, as an esteropeptidase, 19
- 7S-Nerve growth factor precursor, crystal forms, 26
- Neuroectodermal tumours, basic fibroblast growth factor, 108
- Neuron death, prevention by neurotrophic factors, 97, 106
- Neurotrophic factors,
defined, 97
prevention of neuron death, 97, 106
X-ray crystallography, 19–29
- Newt limb blastema, 194
- NIH/3T3 transfectants, 89
activation of α and β -PDGF receptors, 37
- Nuclear localization, *int-2* transcription in COS-1 cells, 91–94
- Nuclear Magnetic Resonance, high resolution, 5–9
- Nuclear Overhauser effects, on TGF and hEGF, 5–9
- Ommatidia, insect compound eye, 157–167
- Oncogenes,
Drosophila, homology to various genes, 184
v-sis, encoding PDGF B chain, 31
- Oscillation mechanisms, Ca²⁺, 1–3
- Osteoblasts, osteoclasts, regulation *see* Bone morphogenetic proteins
- Overhauser effects, on TGF and hEGF, 5–9
- Parietal endoderm, early site of *int-2* gene expression, 90
- Parkinson's disease, chromaffin cell grafting, 108
- Pasteurella multocida* toxin, as mitogen for Swiss 3T3 cells, 52
- Pattern formation, limb regeneration in vertebrates, 191–196
- PCC4 embryonal carcinoma cells, 90
- PDGF *see* Platelet-derived growth factor
- Peripheral nervous system lesions, 107
- Pertussis toxin-sensitive G proteins, 45–46
- Phosphoinositide, breakdown of, 1–3
- Pigment patterns, limb development, 204–205
- Platelet-derived growth factor A and B,
construction of chimeric molecules, 32–34
site-directed mutagenesis, 39
transforming and secretory properties, 31–40
- Platelet-derived growth factor chimeric proteins, 31–40
- Platelet-derived growth factor receptor,
compartmentalization, 36
tyrosine phosphorylation, 37
- PMT *see Pasteurella multocida* toxin
- Polarizing region,
cell–cell interactions in early limb development, 201
gap junction communications, 206
grafted, 202

- Polyphosphoinositides, enzymic breakdown coupled to bombesin receptor, 45–46
- Positional information, limb development, 199–200
- Progesterin, synthetic, 145–146
- Progesterin receptor, binding site for gestodene, 145–146
- Progress zone, limb development, 200
- Protein kinase C,
activation, specific marker, 46
activation by bFGF, 99
- Protein phosphorylation, permeabilized cells, 46–47
- Proteoglycans, binding, and transforming growth factor receptors, 131–137
- Quail, feather patterns, 204–205
- Receptor binding, 5–9, 11–17
tumour necrosis factor, 17
- Retinal precursor cells, insect compound eye ommatidia, 163–165
- Retinoic acid,
cytoplasmic binding protein, blastema, 195
and cytoplasmic binding protein, progress zone, 200
and limb regeneration, 191–196
receptors, 193–194, 196
progress zone, limb development, 200
regulation of gene expression, 194–195
- Retinoids,
morphogenetic effects, 191–196
and steroids, regulation of transforming growth factor-beta, 139–147
- Rhabdomeres, insect compound eye ommatidia, 163
- Rough* homeobox genes, *Drosophila*, 161
- Serine proteases, kallikrein family, 19–29
- Serine/threonine kinase, *Drosophila*, homology to various genes, 184
- Sevenless* gene, *Drosophila*, heat shock-inducible, 162
- Signal transduction, bFGF, 99
- Signals, limb development, 199–206
- Site-specific mutagenesis, 5–9
- Solution structure, 5–9
- Stem cells,
embryonic, growth and differentiation factors, 75–83
inhibitor, action on CSU-S, 64–65
- Steroid hormone superfamily, regulation of transforming growth factor-beta, 139–147
- Swiss 3T3 cells,
model for small cell lung cancer, 44
protein phosphorylation, 46
- TGF *see* Transforming growth factor
- Thrombin, mitogenic stimulation, 1–3
- Transformation mechanism, PDGF, 32–34
- Transforming growth factor receptors,
and binding proteoglycans, 131–137
type I and type II binding proteins, 131–137
- Transforming growth factors,
binding to betaglycan, 135–136
regulation of morphogenesis and differentiation, 131–137
superfamily, 132
- Transforming growth factor-alpha,
structure–function relationships, 5–9
variants, mitogenic activity, 5–9
- Transforming growth factor-beta,
activation by proteases, 131–137
biologically latent form, 143–145
blocking effect of bFGF, 204
distribution in various cell types, 132–133
effects on haemopoietic cells, 64
in limb development, 206
regulation by steroid hormone superfamily, 139–147
subtypes, post-transcriptional regulation, 141–142
- Transforming growth factor-beta-1,
active/latent forms, plasma half-lives, 144
mRNA, potential stem–loop structures, 142
- Transforming growth factor-beta-2, mesoderm inducing factors, 123–126
- Transmembrane signalling, bombesin receptor, 43–53
- Tumorigenesis,
mammary cancer, 87–95, 145
and transforming growth factors, 139–147
- Tumour necrosis factor,
receptor binding, 17
structure and function, 11–17
- Tyrosine kinase receptor, *Drosophila*, homology to various genes, 184
- Tyrosine phosphorylation, platelet-derived growth factor receptor, 37
- Ultrabithorax* gene, *Drosophila*, expression, 162
- Urodele blastema, 194
- V-sis* oncogene, encoding human PDGF B, 31
- Vasopressin, mitogenic stimulation, 1–3
- WEHI-3B cell line, 69–70
- X-ray crystallography,
growth factors, 5–9
murine nerve growth factor, 19–29
tumour necrosis factor, 11–17
- Xenopus*,
growth factors as inducing agents, 119–129
mesoderm induction, 119–129